Otsuka Holdings will pay ICU Medical an upfront payment of $200 million as part of a partnership to enter the U.S. IV products market, which has been facing hurricane-related shortages this fall.

大冢控股将向ICU Medical支付2亿美元的预付款，作为进入美国IV产品市场的合作伙伴关系的一部分，该市场今年秋季一直面临飓风相关的短缺。

The partnership — which involves  ICU Medical providing commercial services for Otsuka’s Otsuka Pharmaceutical Factory (OPF) subsidiary — also includes performance-based milestones at the end of 2026, and a backend put-call option in 2030 and beyond.

该合作关系涉及ICU Medical为大冢的大冢制药厂（OPF）子公司提供商业服务，还包括2026年底基于绩效的里程碑，以及2030年及以后的后端看跌期权。

“Entering the North American market has always been part of our long-term ambition, and this joint venture with ICU Medical is the perfect way to do that.” said Shuichi Takagi, president and representative director of OPF, in a news release out yesterday. “It will allow us to bring our innovative PVC-free technologies — including admixtures, parenteral nutrition in advanced multi-chamber bags, and premix IV antibiotics — to a market with an established customer base.”.

OPF总裁兼代表董事Shuichi Takagi在昨天发布的新闻稿中表示：“进入北美市场一直是我们长期目标的一部分，与ICU Medical的合资企业是实现这一目标的完美途径。”。“这将使我们能够将我们创新的无PVC技术（包括外加剂、先进多室袋中的肠胃外营养以及预混料IV抗生素）推向具有既定客户基础的市场。”。

The move comes more than a month after Hurricane Helene’s remnants hit western North Carolina with heavy rain and flooding. In the process, the storm took out Baxter’s North Cove plant in Marion, North Carolina. Baxter describes the facility, which is its largest, as the largest manufacturer of intravenous and peritoneal dialysis products in the U.S.

飓风海伦的残余物以暴雨和洪水袭击了北卡罗莱纳州西部，一个多月后，美国政府采取了这一行动。在此过程中，暴风雨摧毁了巴克斯特位于北卡罗莱纳州马里恩的北湾工厂。巴克斯特将其最大的工厂描述为美国最大的静脉和腹膜透析产品制造商。

Since then, hospitals across the country have faced disruption in the supply of some sterile intravenous fluids used in everything from intravenous dialysis care to some surgeries..

从那时起，全国各地的医院都面临着一些无菌静脉输液供应的中断，这些输液用于从静脉透析护理到一些手术的各个方面。。

Baxter recently restarted the highest-throughput IV solutions manufacturing line at the North Cove facility.

Baxter最近在North Cove工厂重新启动了吞吐量最高的IV解决方案生产线。

ICU Medical and Otsuka officials see an opportunity to provide extra supply for the U.S. market, as well as supply chain redundancy. They plan to seek import authorization if necessary for the U.S. market while focusing on accelerating new product development. Over the longterm, they plan to seek FDA approval of overseas manufacturing sites..

ICU医疗和大冢的官员看到了为美国市场提供额外供应以及供应链冗余的机会。。从长远来看，他们计划寻求FDA批准海外生产基地。。

Otsuka is the 26th largest pharmaceutical company in the world, according to our sibling Drug Discovery & Development site’s Pharma 50 report, while ICU Medical is 49th in Medical Design & Outsourcing‘s MedTech Big 100.

根据我们的兄弟药物发现与开发网站Pharma 50的报告，大冢是世界上第26大制药公司，而ICU Medical在医疗设计与外包的MedTech Big 100中排名第49位。

“Otsuka’s scale, experience with U.S. partnerships, and demonstrated long-term investment horizon made them the ideal partner,” said ICU Medical CEO Vivek Jain. “Their financial strength and dedication to portfolio expansion will provide the stability and choice the North American market needs. Through this joint venture, we’re committed to delivering clinical and economic value for ICU Medical customers and giving this critical product category the innovation and attention it deserves.”.

ICU医疗首席执行官Vivek Jain表示：“大冢的规模、与美国合作的经验以及长期的投资前景使其成为理想的合作伙伴。”。“他们的财务实力和对投资组合扩展的贡献将为北美市场需求提供稳定性和选择。通过这家合资企业，我们致力于为ICU医疗客户提供临床和经济价值，并为这一关键产品类别提供应有的创新和关注。”。